The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice

@article{Mori2014TheSA,
  title={The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice},
  author={M. Mori and Y. Ueno and Satoshi Konagai and H. Fushiki and Itsuro Shimada and Yutaka Kondoh and Rika Saito and K. Mori and Nobuaki Shindou and T. Soga and H. Sakagami and T. Furutani and Hitoshi Doihara and M. Kudoh and S. Kuromitsu},
  journal={Molecular Cancer Therapeutics},
  year={2014},
  volume={13},
  pages={329 - 340}
}
  • M. Mori, Y. Ueno, +12 authors S. Kuromitsu
  • Published 2014
  • Biology, Medicine
  • Molecular Cancer Therapeutics
  • Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non–small cell lung cancer (NSCLC). Echinoderm microtubule–associated protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC. Here, we investigated the effects of ASP3026, a novel small-molecule ALK inhibitor, against ALK-driven NSCLC. ASP3026 inhibited… CONTINUE READING
    ALK: a tyrosine kinase target for cancer therapy
    • 61
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 50 REFERENCES
    Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
    • 3,969
    • PDF
    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
    • 3,071
    • Highly Influential
    Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
    • 984
    A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    • 493
    • PDF
    Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
    • 183
    • PDF
    CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
    • 464
    • PDF
    EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
    • 998
    • PDF